Metastatic Breast Cancer ( HER2 Negative)

4 clinical trials · Condition

Record	Firm	Date
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer (NCT01268150)	Eisai Inc.	2011-02-01

Every clearance here is in the API, with alerts when new ones post.